Tytuł artykułu
Wybrane pełne teksty z tego czasopisma
Identyfikatory
Warianty tytułu
Języki publikacji
Abstrakty
Dauricine has a variety of pharmacological properties including anti-inflammatory, anti-arrhythmic, and antihypertensive effects as well as reversing multidrug resistance (MDR) of cancer cells. While its therapeutic application is increasing, its bioavailability of different administration routes has not been studied. In the present study, we developed and validated a liquid chromatography/electrospray ionization mass spectrometry method (LC-MS/MS). Using this method, we quantified dauricine in rat plasma after administration via intravenous (i.v.) injection, per oral (p.o.), and intraperitoneal injection (i.p.). Our results indicated that this method detected plasma dauricine with a good linearity in the range of 1.95–1000.00 ng/mL (r = 0.9997). The extraction method showed an average intra- and inter-day recovery of 98.21–104.35% and 98.0–103.58%, respectively. Dauricine showed a fast absorption and widespread distribution after administration in all three tested routes. After intravenous administration (2.5, 5.0, 10.0 mg/kg), the pharmacokinetics of dauricine exhibited a first-order kinetics. In addition, dauricine showed a slow elimination with a long half-life (t1/2z) and double peaks phenomenon following p.o. and i.p. administration. Furthermore, using area under the plasma concentration-time curve (AUC), we calculated absolute bioavailability, which was over twofold higher when administered via i.p. than via p.o. administration. The newly obtained information from our study will provide important reference for dauricine dose and administration route in designing dauricine therapy for applicable diseases.
Słowa kluczowe
Czasopismo
Rocznik
Tom
Strony
241--256
Opis fizyczny
Bibliogr. 18 poz., rys., tab.
Twórcy
autor
- Sichuan University Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy Chengdu, Sichuan China
- Chengdu Medical College Department of Pharmacy Chengdu, Sichuan China
autor
- Sichuan University Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy Chengdu, Sichuan China
autor
- Sichuan University Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy Chengdu, Sichuan China
Bibliografia
- [1] M.C. Li, D.Y. Huang, Chin. Pharm. J., 43, 1875–1877 (2008)
- [2] Z.K. Huang, Modern Journal of Integrated Traditional Chinese and Western Medicine, 13, 718–719 (2004)
- [3] Q.Y. Li, J.Y. Wang, J.J. Cheng, Progress in Veterinary Medicine, 31, 115–117 (2010)
- [4] Pharmacopoeia Commission of People’s Republic of China. Pharmacopoeia of People’s Republic of China, 1st edn. Chemical Industry Press, Beijing, 2005
- [5] Y. Zhang, C. Sun, Q.C. Guan, et al. Modern Pharmacy and Clinic, 24, 367–368 (2009)
- [6] M. Li, B.E. Shan, International Journal of Traditional Chinese Medicine, 27, 267–271 (2005)
- [7] X.Q. Zhu, T.G. Han, Journal of Chengde Medical College, 24, 418–420 (2007)
- [8] X.D. Huang, D. Han, X.Y. Cui, Medical Journal of Chinese People’s Health, 19, 575–576 (2007)
- [9] J.Q. Qian, Acta Pharmacol Sin, 23, 1086–1092 (2002)
- [10] H. Tian, Q.C. Pan, Cancer, 15, 410–414 (1996)
- [11] J.H. Li, F.Q. Qin, P.M. Yang, Journal of Dalian Medical University, 24, 94–96 (2002)
- [12] L. He, G.Q. Liu, Acta Pharmacol Sin, 23, 591–596 (2002)
- [13] F.M. Han, Z.H. Peng, W. Song, et al. Journal of Chromatography B, 854, 1–7 (2007)
- [14] X.Y. Liu, Q. Liu, D.M. Wang, et al. Journal of Chromatography B, 878, 1199–1203 (2010)
- [15] S.J. Chen, B. Zhang, Y.M. Yang, Z.S. Dai, et al. Chinese Journal Of Clinical Pharmacology and Therapeutics, 5, 213–217 (2000)
- [16] S.J. Chen, Y.M. Yang, Chinese Pharmacological Bulletin, 17, 225–229 (2001)
- [17] R. Sun, C. Wang, Chinese Journal of Pharmacovigilance, 6, 546–549 (2009)
- [18] V.J. Wacher, L. Salphati, L.Z. Benet, Advanced Drug Delivery Reviews, 46, 89–102 (2001)
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-5124c181-c2bc-45f9-9413-b2164dcfdcae